Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Accumulated Depreciation & Amortization (2020 - 2023)

Historic Accumulated Depreciation & Amortization for Candel Therapeutics (CADL) over the last 4 years, with Q3 2023 value amounting to $1.8 million.

  • Candel Therapeutics' Accumulated Depreciation & Amortization rose 82000.0% to $1.8 million in Q3 2023 from the same period last year, while for Sep 2023 it was $1.8 million, marking a year-over-year increase of 82000.0%. This contributed to the annual value of $800000.0 for FY2022, which is 30000.0% up from last year.
  • Latest data reveals that Candel Therapeutics reported Accumulated Depreciation & Amortization of $1.8 million as of Q3 2023, which was up 82000.0% from $200000.0 recorded in Q2 2023.
  • Over the past 5 years, Candel Therapeutics' Accumulated Depreciation & Amortization peaked at $1.8 million during Q3 2023, and registered a low of $7000.0 during Q2 2021.
  • Its 4-year average for Accumulated Depreciation & Amortization is $289428.6, with a median of $200000.0 in 2021.
  • As far as peak fluctuations go, Candel Therapeutics' Accumulated Depreciation & Amortization crashed by 6818.18% in 2021, and later surged by 275714.29% in 2022.
  • Candel Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $91000.0 in 2020, then surged by 119.78% to $200000.0 in 2021, then skyrocketed by 300.0% to $800000.0 in 2022, then soared by 130.0% to $1.8 million in 2023.
  • Its Accumulated Depreciation & Amortization stands at $1.8 million for Q3 2023, versus $200000.0 for Q2 2023 and $200000.0 for Q1 2023.